Impact of an Antimicrobial Stewardship Policy to Restrict Palivizumab Use.
作者信息
Joerger Torsten, Chan Shannon, Swami Sanjeev K, Handy Lori K
机构信息
Division of Infectious Diseases, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
Department of Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware.
出版信息
J Pediatric Infect Dis Soc. 2019 May 11;8(2):189-190. doi: 10.1093/jpids/pix091.
Abstract
摘要
相似文献
1
Impact of an Antimicrobial Stewardship Policy to Restrict Palivizumab Use.一项限制帕利珠单抗使用的抗菌药物管理政策的影响
J Pediatric Infect Dis Soc. 2019 May 11;8(2):189-190. doi: 10.1093/jpids/pix091.
2
Re-evaluating the New Committee on Infectious Diseases Recommendations for Palivizumab Use in Premature Infants.重新评估传染病新委员会关于帕利珠单抗用于早产儿的建议。
Pediatr Infect Dis J. 2015 Sep;34(9):958-60. doi: 10.1097/INF.0000000000000808.
3
Antimicrobial Stewardship Programs (ASP): Perspective on Problems and Potential.抗菌药物管理计划（ASP）：问题与潜力之展望
R I Med J (2013). 2018 Jun 1;101(5):18-21.
4
Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.帕利珠单抗在囊性纤维化婴幼儿中安全性和有效性的系统评价
Pharmacotherapy. 2017 Jun;37(6):755-769. doi: 10.1002/phar.1936. Epub 2017 May 29.
5
Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.在帕利珠单抗时代，胎龄28周及以下婴儿因呼吸道合胞病毒住院的情况。
Int J Infect Dis. 2017 Apr;57:50-53. doi: 10.1016/j.ijid.2017.01.034. Epub 2017 Feb 2.
6
Efficacy and long-term outcomes of palivizumab prophylaxis to prevent respiratory syncytial virus infection in infants with cystic fibrosis in Northern Ireland.在北爱尔兰，帕利珠单抗预防囊性纤维化婴儿呼吸道合胞病毒感染的疗效及长期结果
Pediatr Pulmonol. 2016 Apr;51(4):379-85. doi: 10.1002/ppul.23376. Epub 2016 Jan 25.
7
Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands.在荷兰，妊娠32周前出生的婴儿或患有呼吸系统疾病的婴儿最有可能接受帕利珠单抗治疗。
Acta Paediatr. 2015 Sep;104(9):927-32. doi: 10.1111/apa.13081. Epub 2015 Jul 23.
8
Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.加拿大帕利珠单抗登记处中帕利珠单抗预防呼吸道合胞病毒的依从性。
Pediatr Infect Dis J. 2015 Dec;34(12):e290-7. doi: 10.1097/INF.0000000000000922.
9
Computer-Assisted Antimicrobial Recommendations for Optimal Therapy: Analysis of Prescribing Errors in an Antimicrobial Stewardship Trial.计算机辅助抗菌药物推荐以实现最佳治疗：抗菌药物管理试验中处方错误分析。
Infect Control Hosp Epidemiol. 2017 Jul;38(7):857-859. doi: 10.1017/ice.2017.74. Epub 2017 Jun 2.
10
[Recommendations for palivizumab use. Update 2015].[帕利珠单抗使用建议。2015年更新]
Arch Argent Pediatr. 2016 Feb;114(1):84-8. doi: 10.5546/aap.2016.84.
本文引用的文献
1
Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.呼吸道合胞病毒感染对足月儿和早产儿住院治疗的结局及费用影响
J Perinatol. 2016 Nov;36(11):990-996. doi: 10.1038/jp.2016.113. Epub 2016 Aug 4.
2
Implementation of American Academy of Pediatrics guidelines for palivizumab prophylaxis in a pediatric hospital.一家儿科医院实施美国儿科学会关于帕利珠单抗预防的指南。
Am J Health Syst Pharm. 2016 Mar 15;73(6):405-8. doi: 10.2146/ajhp150499.
3
Use of electronic health records and clinical decision support systems for antimicrobial stewardship.电子病历和临床决策支持系统在抗菌药物管理中的应用。
Clin Infect Dis. 2014 Oct 15;59 Suppl 3:S122-33. doi: 10.1093/cid/ciu565.
4
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.呼吸道合胞病毒感染住院风险增加的婴幼儿使用帕利珠单抗预防的更新指南。
Pediatrics. 2014 Aug;134(2):415-20. doi: 10.1542/peds.2014-1665.
5
The burden of respiratory syncytial virus infection in young children.幼儿呼吸道合胞病毒感染的负担
N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/NEJMoa0804877.
Zotero 插件